NCT06331715View on ClinicalTrials.gov

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 6, 2024

Primary Completion Date

April 1, 2024

Study Completion Date

May 31, 2024

Conditions

Bioequivalence

Interventions

DRUG

Palbociclib 125mg

Pharmacokinetic parameters AUC and Cmax will be evaluated to establish bioequivalence betweeen the Test and Reference products

Trial Locations (1)

Unknown

Azidus Laboratories, Chennai

All Listed Sponsors

lead

Megalabs

INDUSTRY

NCT06331715 - Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg | Biotech Hunter | Biotech Hunter